drugset / Trial / NCT01617239

Clinical Study for Safety and Immunogenicity Study of Influenza Vaccine

NCT01617239

Phase 1 Completed 84 enrolled Crucell Holland BV
RandomizedParallel-groupOpen-labelPrevention

Summary

The goal of the study is to assess the safety and immune response after vaccination with different doses and vaccination schedules of virosomal influenza vaccine.

Timeline

Start
2012-06
Primary completion
2013-06
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Inflexal V Vaccine 0.5 ml Intramuscular
Subject Inflexal V Vaccine 1 ml Intramuscular
Subject Inflexal V Vaccine 1.5 ml Intramuscular

Indications